Share this article on:

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study

Kunzmann, Volker MD; Ramanathan, Ramesh K. MD; Goldstein, David MBBS, FRACP, FRCP; Liu, Helen MD, MS; Ferrara, Stefano PharmD; Lu, Brian MD, PhD; Renschler, Markus F. MD; Von Hoff, Daniel D. MD, FACP

doi: 10.1097/MPA.0000000000000742
Original Articles

Objectives Results from the phase 3 Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) led to approval of nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer. The current analysis evaluated the effects of nab-paclitaxel plus gemcitabine versus gemcitabine on primary pancreatic and metastatic lesions.

Methods In this analysis of the previously described MPACT trial, changes in pancreatic and metastatic tumor burden were assessed using independently measured diameters of lesions on computed tomography or magnetic resonance imaging scans. Changes in the sums of longest tumor diameters were summarized using descriptive statistics and were included in a multivariate analysis of overall survival.

Results Primary pancreatic lesion measurement was feasible. Reductions in primary pancreatic tumor burden and metastatic burden from baseline to nadir were significantly greater with nab-paclitaxel plus gemcitabine versus gemcitabine. Baseline pancreatic tumor burden was independently predictive of survival. Both regimens elicited linear reductions in primary pancreatic and metastatic tumor burden through time. There was a high within-patient concordance of tumor changes between primary pancreatic lesions and metastatic lesions.

Conclusions This analysis of MPACT demonstrated significant tumor shrinkage benefit for nab-paclitaxel plus gemcitabine in both primary pancreatic and metastatic lesions, supporting ongoing evaluation of this regimen in locally advanced disease.

From the *Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany; †Mayo Clinic, Scottsdale, AZ; ‡Prince of Wales Hospital, Sydney, New South Wales, Australia; §Celgene Corporation, Summit, NJ; and ∥Translational German Research Institute and Honor Health Research Institute, Scottsdale, AZ.

Received for publication March 1, 2016; accepted September 7, 2016.

Address correspondence to: Volker Kunzmann, MD, Medizinische Klinik und Poliklinik II, University of Würzburg, Zentrum für Innere Medizin (A3.-1.919), Oberduerrbacher Str 6, 97080 Würzburg, Germany (e-mail:

This study was supported by Celgene Corporation.

V.K. has a consultant/advisory role and receives research funding from Celgene. R.R. has a consultant/advisory role and receives honoraria and research funding from Celgene. D.G. has a consultant/advisory role and receives research funding from Celgene. H.L., S.F., B.L., and M.R. are employees of and have stock ownership in Celgene. D.V.F. has a consultant/advisory role and receives honoraria from Celgene and receives research funding from Honor Health.

The authors were fully responsible for all content and editorial decisions for this article.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.